Biofourmis and HealthXL Report: Digital Endpoint Support for Pharma Label Claims Expected to Become Common Before 2030
BOSTON, Nov. 16, 2023 /PRNewswire/ -- An industry report released today forecasts that digital endpoints will see broader adoption in supporting pharmaceutical and life science label claims in the years ahead—but only after industry-wide, pre-competitive collaboration aimed at standardization and proactive sharing of data around clinically validated patient-centric outcomes. This is one of the main findings presented in a report by Biofourmis, a leading global technology-enabled clinical research and care delivery company, and HealthXL, a leading market intelligence platform and community for health technology and digital health globally.
- The report, "Unlocking the Value of Digital Measures in Drug Development," delves deep into the trends and opportunities of using digital measures in pharmaceutical R&D.
- Additionally, the report draws insights from recent trends and developments in digital endpoints and biomarkers analyzed by Biofourmis and HealthXL.
- As of November 1, the Digital Medicine Society's Crowdsourced Library of Digital Endpoints had reached 430, with nearly 80% of the listings added in 2019 or later.
- "Numerous experts and senior executives stressed the importance of open-source collaboration on digital endpoint development.